Significant Medicare Part B reimbursement rate cuts and burdensome claim modifiers apply to certain drugs purchased by hospitals through the 340B drug discount program effective on Jan. 1, 2018 after a federal judge declined to hear a case brought by 340B stakeholders. Read the opinion here and Polsinelli’s analysis of CMS’s 2018 OPPS payment adjustment rule (Final Rule).

Continue reading on The National Law Review.